ArticleMolecular therapy. Nucleic acids2017
Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology.
Article in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Decoy DNA Protects Molecular Tension Probes from DNase Degradation.Angewandte Chemie (International ed. in English) · 2025Article
- Optimizing Detection of Circulating Tumor Cells in Breast Cancer: Unveiling New Markers for Clinical Applications.International journal of molecular sciences · 2025Article
- Current Trends in Liquid Biopsy Tracking Resistance in Molecular Breast Cancer-Targeted Therapies.Genes · 2025Review
- Circulating tumour DNA as a promising biomarker for breast cancer diagnosis & treatment monitoring.The Indian journal of medical research · 2025Review
- Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.Cancer science · 2024Review
- Review
- Liquid Biopsy as a Tool for the Diagnosis, Treatment, and Monitoring of Breast Cancer.International journal of molecular sciences · 2022Review
- From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine.Cancers · 2022Review
- Breast cancer circulating tumor cells with mesenchymal features-an unreachable target?Cellular and molecular life sciences : CMLS · 2022Review
- Circulating tumor cells in the early detection of human cancers.International journal of biological sciences · 2022Review
- Nucleases as molecular targets for cancer diagnosis.Biomarker research · 2021Review
- Discovery and Proof-of-Concept Study of Nuclease Activity as a Novel Biomarker for Breast Cancer Tumors.Cancers · 2021Article
- Detection Methods and Clinical Applications of Circulating Tumor Cells in Breast Cancer.Frontiers in oncology · 2021Review
- Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism.Scientific reports · 2020Article
- Optical sensor revealed abnormal nuclease spatial activity on cancer cell membrane.Journal of biophotonics · 2019Article
- Review
- Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
Abstract
A challenge for circulating tumor cell (CTC)-based diagnostics is the development of simple and inexpensive methods that reliably detect the diverse cells that make up CTCs. CTC-derived nucleases are one category of proteins that could be exploited to meet this challenge. Advantages of nucleases as CTC biomarkers include: (1) their elevated expression in many cancer cells, including cells implicated in metastasis that have undergone epithelial-to-mesenchymal transition; and (2) their enzymatic activity, which can be exploited for signal amplification in detection methods. Here, we describe a diagnostic assay based on quenched fluorescent nucleic acid probes that detect breast cancer CTCs via their nuclease activity. This assay exhibited robust performance in distinguishing breast cancer patients from healthy controls, and it is rapid, inexpensive, and easy to implement in most clinical labs. Given its broad applicability, this technology has the potential to have a substantive impact on the diagnosis and treatment of many cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.